Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
- 26 May 2020
- journal article
- letter
- Published by Elsevier BV in Journal of Infection
- Vol. 82 (1), 159-198
- https://doi.org/10.1016/j.jinf.2020.05.039
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort studyJournal of Infection, 2020
- Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved DrugsAntimicrobial Agents and Chemotherapy, 2020
- Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infectionEuropean Respiratory Journal, 2020
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19The New England Journal of Medicine, 2020
- Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infectionPublished by Cold Spring Harbor Laboratory ,2020
- Covid-19 — Navigating the UnchartedThe New England Journal of Medicine, 2020
- The First Locally Acquired Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in a Healthcare Worker in the Paris AreaClinical Infectious Diseases, 2020
- Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCREurosurveillance, 2020
- Drug for corona virus: A systematic reviewIndian Journal of Pharmacology, 2020
- Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective studyThe Lancet, 2003